Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 14/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.74 |
| ▸ | FABP3 | P05413 | 1/20 | 0.62 |
| ▸ | FABP4 | P15090 | 1/20 | 0.62 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22481076 | 0.89 | MRGPRX4 (0.80) | MRGPRX4TP53HTTFABP3FABP4 | |
| SCHEMBL8783044 | 0.89 | MRGPRX4 (0.80) | MRGPRX4TP53HTTFABP3FABP4 | |
| SCHEMBL16273719 | 0.89 | MRGPRX4 (0.80) | MRGPRX4TP53HTTFABP3FABP4 | |
| SCHEMBL22469930 | 0.87 | MRGPRX4 (1.00) | MRGPRX4TP53HTTFABP3FABP4 | |
| SCHEMBL31568543 | 0.87 | MRGPRX4 (1.00) | MRGPRX4TP53HTTFABP3FABP4 | |
| SCHEMBL22481075 | 0.87 | MRGPRX4 (1.00) | MRGPRX4TP53HTTFABP3FABP4 | |
| SCHEMBL31568443 | 0.87 | MRGPRX4 (1.00) | MRGPRX4TP53HTTFABP3FABP4 | |
| SCHEMBL6386587 | 0.86 | MRGPRX4 (0.76) | MRGPRX4TP53HTTFABP3FABP4 | |
| SCHEMBL3555045 | 0.86 | MRGPRX4 (0.76) | MRGPRX4TP53HTTFABP3FABP4 | |
| SCHEMBL17616605 | 0.86 | MRGPRX4 (0.76) | MRGPRX4TP53HTTNPC1CLCN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-11643399-B2 | Modulators of mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643399-B2 | Modulators of mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20230053860-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2023-02-23 | — | — | US | disclosed |
| US-20210032213-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2021-02-04 | — | — | US | disclosed |
| WO-2020198537-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | MRGPRX4 1/4885TP53 4046/4885HTT 3700/4885 |
| US-11643399-B2 | Modulators of mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | MRGPRX4 1/4885TP53 4046/4885HTT 3700/4885 |
| US-20210032213-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | MRGPRX4 1/4885TP53 4026/4885HTT 3703/4885 |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | MRGPRX4 1/4885TP53 4046/4885HTT 3700/4885 |
| US-20230053860-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | MRGPRX4 1/4885TP53 4046/4885HTT 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.